Profile data is unavailable for this security.
About the company
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
- Revenue in INR (TTM)5.79bn
- Net income in INR403.74m
- Incorporated1958
- Employees394.00
- LocationKopran LtdParijat House1076, Dr. E. Moses Road, Worli9917MUMBAI 400018IndiaIND
- Phone+91 2 243661111
- Fax+91 2 224950363
- Websitehttps://www.kopran.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panacea Biotec Ltd | 5.52bn | -119.17m | 8.20bn | 1.09k | -- | -- | 15.94 | 1.49 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
| Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.41bn | 1.06k | 39.51 | -- | 17.15 | 1.69 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
| Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 8.57bn | 940.00 | 34.87 | -- | 32.64 | 3.89 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
| Vimta Labs Ltd | 3.20bn | 413.41m | 10.81bn | 1.37k | 26.54 | -- | 14.32 | 3.37 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 10.90bn | 38.00 | 115.79 | 41.96 | 121.40 | 24.21 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Windlas Biotech Ltd | 6.00bn | 526.38m | 11.15bn | 1.05k | 21.28 | -- | 16.86 | 1.86 | 25.18 | 25.18 | 286.98 | -- | -- | -- | -- | 5,723,394.00 | -- | -- | -- | -- | 37.06 | -- | 8.77 | -- | -- | 59.55 | -- | -- | 10.12 | -- | 11.91 | -- | -- | -- |
| Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 11.50bn | 763.00 | 15.51 | 1.19 | 10.65 | 1.49 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.74bn | 1.70k | 13.45 | -- | 12.02 | 2.13 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
| Kopran Ltd | 5.79bn | 403.74m | 11.95bn | 394.00 | 29.79 | -- | 22.58 | 2.06 | 8.32 | 8.32 | 119.70 | -- | -- | -- | -- | 14,693,070.00 | -- | 8.64 | -- | 12.88 | 35.60 | 34.36 | 6.97 | 8.71 | -- | 36.80 | -- | -- | 15.38 | 11.85 | -55.38 | 5.86 | 39.08 | -- |
| Beta Drugs Ltd | 2.56bn | 347.57m | 12.64bn | 315.00 | 36.37 | 8.90 | 27.62 | 4.94 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Zota Health Care Ltd | 1.68bn | -100.65m | 12.76bn | 338.00 | -- | -- | 179.72 | 7.61 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
| Syncom Formulations (India) Ltd | 2.50bn | 263.83m | 12.88bn | 799.00 | 40.29 | -- | 41.57 | 5.16 | 0.34 | 0.34 | 3.26 | -- | -- | -- | -- | 3,126,329.00 | -- | 7.69 | -- | 10.30 | 39.33 | 31.92 | 10.56 | 8.73 | -- | 4.72 | -- | -- | 2.09 | 7.17 | 1.42 | 18.34 | 25.48 | -- |
| Ngl Fine Chem Ltd | 3.17bn | 380.04m | 14.56bn | 343.00 | 38.30 | -- | 29.27 | 4.59 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| Hester Biosciences Ltd | 3.05bn | 188.89m | 14.86bn | 693.00 | 70.19 | 5.09 | 38.76 | 4.88 | 24.89 | 24.89 | 392.38 | 343.01 | 0.4572 | 1.20 | 3.85 | -- | 3.18 | 6.15 | 4.00 | 7.69 | 68.52 | 68.83 | 6.95 | 12.83 | 1.31 | 1.84 | 0.4466 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
Data as of May 15 2024. Currency figures normalised to Kopran Ltd's reporting currency: Indian Rupee INR
1.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Apr 2024 | 450.00k | 0.93% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 46.40k | 0.10% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 25.23k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 821.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 307.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 09 May 2024Source: FactSet Research Systems Inc.
